Table 1.
Summary of demographic information in patients with BP.
| Demographics | Rituximab | Omalizumab | Dupilumab | Total |
|---|---|---|---|---|
| Patients, n (%) | 122 (100.0) | 53 (100.0) | 36 (100.0) | 211 (100.0) |
| Sex, n (%) | ||||
| Female | 53 (43.4) | 24 (45.3) | 15 (41.7) | 92 (43.6) |
| Male | 45 (36.9) | 26 (49.1) | 18 (50.0) | 89 (42.2) |
| NR | 24 (19.7) | 3 (5.7) | 3 (8.3) | 30 (14.2) |
| Age, y | ||||
| Mean | 65.9 | 68.2 | 74.3 | 68.0 |
| Range | 0.3-88 | 0.4-95.0 | 22.0-91.0 | 0.3-95.0 |
| NR, n (%) | 15 (12.3) | 2 (3.8) | 3 (8.3) | 20 (9.5) |
| BP duration, months | ||||
| Mean | 25.4 | 9.6 | 19.2 | 19.3 |
| Range | 1.0-92.0 | 1.0-48.0 | 1.0-240.0 | 1.0-240.0 |
| NR, n (%) | 59 (48.4) | 14 (26.4) | 3 (8.3) | 76 (36.0) |
| Follow-up period, months | ||||
| Mean | 21.9 | 5.6 | 8.6 | 19.1 |
| Range | 1.0-38.0 | 2.0-10.0 | 5.0-12.0 | 1.0-38.0 |
| NR, n (%) | 23 (18.9) | 36 (67.9) | 31 (86.1) | 90 (42.7) |
| Detected antibodies, n (%) | ||||
| Anti-BP180 IgG + | 80 (65.6) | 25 (47.2) | 3 (8.3) | 108 (51.2) |
| Anti-BP230 IgG + | 59 (48.4) | 14 (26.4) | 1 (2.8) | 74 (35.1) |
| NR, n (%) | 40 (32.8) | 26 (49.1) | 33 (91.7) | 99 (46.9) |
| Anti-BP180 IgE + | N/A | 4 (7.5) | 0 (0.0) | 4 (1.9) |
| Anti-BP230 IgE + | N/A | 3 (5.7) | 0 (0.0) | 3 (1.4) |
| Elevated total IgE | N/A | 34 (64.2) | 6 (16.7) | 40 (19.0) |
| Eosinophilia, n (%) | N/A | 18 (34.0) | 4 (11.1) | 22 (10.4) |
| Previous treatment for BP, n (%) | ||||
| Corticosteroids | 67 (54.9) | 51 (96.2) | 24 (66.7) | 142 (67.3) |
| Immunosuppressants | ||||
| Methotrexate | 13 (10.7) | 5 (9.4) | 8 (22.2) | 26 (12.3) |
| Mycophenolate mofetil | 22 (18.0) | 7 (13.2) | 5 (13.9) | 34 (16.1) |
| Azathioprine | 14 (11.5) | 9 (17.0) | 2 (5.6) | 25 (11.8) |
| Cyclosporine | 5 (4.1) | 1 (1.9) | 1 (2.8) | 7 (3.3) |
| Cyclophosphamide | 6 (4.9) | 2 (3.8) | 1 (2.8) | 9 (4.7) |
| Tacrolimus | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Antibiotics | ||||
| Dapsone | 22 (18.0) | 7 (13.2) | 1 (2.8) | 30 (14.2) |
| Doxycycline | 2 (1.6) | 11 (20.8) | 6 (16.7) | 19 (9.0) |
| Minocycline | 4 (3.3) | 2 (3.8) | 0 (0.0) | 6 (2.8) |
| Tetracycline | 0 (0.0) | 3 (5.7) | 0 (0.0) | 3 (1.4) |
| Azithromycin | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (0.5) |
| Nicotinamide | 4 (3.3) | 7 (13.2) | 5 (13.9) | 16 (7.6) |
| Intravenous immunoglobulin | 15 (12.3) | 11 (20.8) | 5 (13.9) | 31 (14.7) |
| Immunoadsorption | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Plasma exchange | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Antihistamines | 2 (1.6) | 5 (9.4) | 1 (2.8) | 8 (3.8) |
| Rituximab | N/A | 6 (11.3) | 2 (5.6) | 8 (3.8) |
| Omalizumab | 1 (0.8) | N/A | 5 (13.9) | 6 (2.8) |
| None | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| NR | 47 (38.5) | 0 (0.0) | 8 (22.2) | 55 (26.1) |
| Concomitant treatment, n (%) | ||||
| Corticosteroids | 86 (70.5) | 36 (67.9) | 23 (63.9) | 145 (68.7) |
| Immunosuppressants | ||||
| Azathioprine | 4 (3.3) | 3 (5.7) | 9 (25.0) | 16 (7.6) |
| Methotrexate | 4 (3.3) | 0 (0.0) | 3 (8.3) | 7 (3.3) |
| Mycophenolate mofetil | 10 (8.2) | 2 (3.8) | 2 (5.6) | 14 (6.6) |
| Cyclophosphamide | 1 (0.8) | 0 (0.0) | 1 (2.8) | 2 (0.9) |
| Cyclosporine | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Antibiotics | ||||
| Dapsone | 6 (4.9) | 1 (1.9) | 0 (0.0) | 7 (3.3) |
| Doxycycline | 3 (2.5) | 7 (13.2) | 2 (5.6) | 12 (5.7) |
| Tetracycline | 0 (0.0) | 1 (1.9) | 0 (0.0) | 1 (0.5) |
| Nicotinamide | 0 (0.0) | 2 (3.8) | 1 (2.8) | 3 (1.4) |
| Intravenous immunoglobulin | 17 (13.9) | 1 (1.9) | 0 (0.0) | 18 (8.5) |
| Plasma exchange | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Immunoadsorption | 3 (2.5) | 0 (0.0) | 0 (0.0) | 3 (1.4) |
| Antihistamines | 0 (0.0) | 6 (11.3) | 0 (0.0) | 6 (2.8) |
| Daclizumab | 1 (0.8) | 0 (0.0) | 0 (0.0) | 1 (0.5) |
| Omalizumab | 0 (0.0) | N/A | 1 (2.8) | 1 (0.5) |
| None | 14 (11.5) | 8 (15.1) | 3 (8.3) | 25 (11.8) |
| NR | 40 (32.8) | 5 (9.4) | 1 (2.8) | 46 (21.8) |
BP, bullous pemphigoid; NR, not reported; N/A, not applicable.